

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Metis TechBio Co., Ltd.

剂泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

VOLUNTARY ANNOUNCEMENT

METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE FORMULATION PLATFORM

This announcement is made by Metis TechBio Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Metis TechBio**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company’s independently developed AiTEM artificial intelligence formulation innovation platform will be deployed locally at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276SH; 01276HK) to enhance the efficiency of drug formulation development. This collaboration marks the continued external commercialisation of the NanoForge-powered AiTEM artificial intelligence (“**AI**”) formulation innovation platform, initiating the process of NanoForge empowering a new generation of intelligent research and development infrastructure.

NanoForge is the world’s first AI-driven nano-delivery platform independently developed by Metis TechBio. It features the world’s first AI for Nano lipid de novo generation algorithm, a foundational lipid language model, METiS agent and a high-throughput wet and dry experiment closed-loop iteration platform, and has become a key AI for Science infrastructure for drug delivery. As of May 2026, NanoForge has accumulated over 10 million lipid structures and 100,000 experimental data points, empowering Metis TechBio’s research and development team to advance more than 10 industry-first or best-in-class pipelines, with breakthrough progress in targeted delivery to eight key human organs and tissues.

AiTEM is powered by Metis TechBio's proprietary AI nano-delivery platform NanoForge, and uses proprietary algorithms for drug formulation design and optimisation. Through quantum chemistry and molecular dynamics simulations, the platform predicts interactions between drugs and excipients, generating optimised formulations for various dosage forms to improve drug solubility, permeability and bioavailability, and to achieve ideal pharmacokinetic profiles. In MTS-004, the first AI-enabled formulation new drug in China to complete Phase III clinical trials, AiTEM undertook the modelling and predictive analysis for formulation development, shortening the preclinical formulation optimisation cycle from the industry average of one to two years to within three months. From project initiation to completion of Phase III clinical trials, MTS-004 took only 38 months, significantly improving drug research and development efficiency compared with the industry average.

ABOUT METIS TECHBIO

Metis TechBio was co-founded in 2020 by Dr. Hongming Chen, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Tsai-Ta Lai and Dr. Wenshou Wang. The Company was successfully listed on the Hong Kong Stock Exchange on May 13, 2026 as the “world's first listed company of AI drug delivery”. The Company has independently developed NanoForge, the world's first AI-driven nano-delivery platform, and owns the world's largest proprietary LNP lipid library with over 10 million lipids. Based on NanoForge, the Company has built four core solutions: AiLNP (AI nano-delivery system design platform), AiRNA (AI mRNA sequence design platform), AiProtein (AI protein design platform), and AiTEM (AI small molecule formulation design platform).

The Company has achieved the capability for precise and targeted delivery to eight key organs or tissues, including the liver, lungs, muscles and immune cells, and has made breakthrough progress in addressing the challenge of multi-organ and multi-tissue targeted delivery, providing druggability opportunities for oncology, metabolic diseases, autoimmune diseases and neurodegenerative diseases, while also offering the potential for anti-aging at the organ level.

FORWARD-LOOKING STATEMENTS

There is no assurance that any forward-looking statements contained in this announcement regarding the Group's business development, or any matter, will be achieved, will actually occur, will be realised or are complete or accurate. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai

Chairman of the Board, executive Director and chief executive officer

Hong Kong, August 3, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.